Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08828079.7Aexternal-prioritypatent/EP2145002B1/en
Άθικτα μικροκύτταρα βακτηριακής προέλευσης μπορούν με ασφάλεια να εισάγουν θεραπευτικώς αποτελεσματικές ποσότητες λειτουργικό νουκλεϊκό οξύ απαλλαγμένο από πλασμίδιο για να στοχεύουν κύτταρα θηλαστικού. Προς αυτό τον σκοπό, λειτουργικό νουκλεϊκό οξύ μπορεί να συσκευαστεί απευθείας μέσα σε άθικτα μικροκύτταρα, χωρίς προσφυγή σε κατασκευάσματα έκφρασης, στην μηχανική έκφρασης του κυττάρου ξενιστή, σε σκληρές χημικές ουσίες ή ηλεκτροδιάτρηση.Intact microbial cells of bacterial origin can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged directly into intact microcytes without resorting to expression constructs, host cell expression machinery, harsh chemicals or electroporation.
CY20151100315T2007-03-302015-03-31
BACTERIAL ORIGINAL MICROCELLULAR INCLUSIONS CONTAINING A FUNCTIONAL ACID-FREE PLUMBLE FOR IN VIVO HORIZON
CY1116310T1
(en)
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
peptonucleic acid derivative, pharmaceutical composition containing a therapeutically effective amount of the peptonucleic acid derivative, method of using the peptonucleic acid derivative and compound
Transfer vector for inserting a gene into a genetic locus of a baculovirus sequence; procedure to produce a recombinant bacmidium; recombinant bacmidium; cell containing a transfer vector
METHODS AND KITS TO DETECT NUCLEIC ACIDS THAT ARE EXCLUSIVE FOR EVENT DP-032218-9 AND FOR DETERMINING THE ZYGOSITY OF A NUCLEIC ACID EXCLUSIVE FOR EVENT DP-032218-9